FDA ac­cepts In­tel­li­a's IND for CRISPR and TCR-T cell ther­a­py; San­té clos­es Fund IV at $260M

Rid­ing the coat­tails of a mas­sive $600 mil­lion cash raise in June, In­tel­lia an­nounced that the FDA ac­cept­ed their IND ap­pli­ca­tion for their gene edit­ing treat­ment NT­LA-5001, built as a treat­ment for acute myeloid leukemia.

The Cam­bridge, MA biotech said that they have plans to start pa­tient screen­ing in a Phase I/IIa study by the end of 2021. The study will eval­u­ate the ef­fects of a sin­gle dose of the treat­ment in adults who have de­tectable AML af­ter hav­ing re­ceived stan­dard first-line ther­a­py. The study will con­tain a dose es­ca­la­tion and ex­pan­sion phase, with up to 54 par­tic­i­pants.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER